Insmed reported $142M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Cytokinetics USD 1.93M 64.83M Sep/2025
DBV Technologies USD 2.77M 1.31M Sep/2025
Dynavax Technologies USD 94.9M 540K Sep/2025
Gilead Sciences USD 7.8B 700M Sep/2025
Insmed USD 142M 34.6M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025